INCY vs TTRX
INCY: A biopharmaceutical company pioneering targeted therapies for blood cancers and inflammatory diseases, with flagship JAK inhibitor JAKAFI generating substantial cash flow. TTRX: Turn Therapeutics is developing a non-systemic topical immunomodulator (GX-03) containing polyhexanide for moderate-to-severe eczema and onychomycosis, with topline results expected mid-2026.
Side-by-side fundamentals
| Metric | INCY | TTRX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $115.79 | $9.62 | |
| Market cap as of 2026-07-23 | $23.3B | $301M | |
| P/E as of 2026-07-23 | 16.29 | n/a | |
| PEG as of 2026-07-23 | 1.00 | n/a | |
| Net margin as of 2026-07-23 | +26.7% | n/a | |
| Gross margin as of 2026-07-23 | +93.0% | n/a | |
| Operating margin as of 2026-07-23 | +30.1% | n/a | |
| ROE as of 2026-07-23 | +29.2% | -117.3% | INCY higher |
| ROA as of 2026-07-23 | +21.6% | -38.9% | INCY higher |
| Debt / equity as of 2026-07-23 | 0.01 | 0.97 | INCY lower |
| Revenue growth (YoY) as of 2026-07-23 | +21.5% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +14.8% | n/a | |
| Beta as of 2026-07-23 | 0.77 | 0.09 | |
| 1-year return as of 2026-07-22 close | +74.2% | +158.4% | TTRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.